JP2008505857A5 - - Google Patents

Download PDF

Info

Publication number
JP2008505857A5
JP2008505857A5 JP2007518053A JP2007518053A JP2008505857A5 JP 2008505857 A5 JP2008505857 A5 JP 2008505857A5 JP 2007518053 A JP2007518053 A JP 2007518053A JP 2007518053 A JP2007518053 A JP 2007518053A JP 2008505857 A5 JP2008505857 A5 JP 2008505857A5
Authority
JP
Japan
Prior art keywords
antigen
irm compound
subject
combination
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007518053A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008505857A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/014746 external-priority patent/WO2006126981A2/en
Publication of JP2008505857A publication Critical patent/JP2008505857A/ja
Publication of JP2008505857A5 publication Critical patent/JP2008505857A5/ja
Withdrawn legal-status Critical Current

Links

JP2007518053A 2004-04-28 2005-04-28 粘膜ワクチン接種のための組成物および方法 Withdrawn JP2008505857A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56612104P 2004-04-28 2004-04-28
PCT/US2005/014746 WO2006126981A2 (en) 2004-04-28 2005-04-28 Compositions and methods for mucosal vaccination

Publications (2)

Publication Number Publication Date
JP2008505857A JP2008505857A (ja) 2008-02-28
JP2008505857A5 true JP2008505857A5 (enExample) 2008-06-19

Family

ID=37452481

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007518053A Withdrawn JP2008505857A (ja) 2004-04-28 2005-04-28 粘膜ワクチン接種のための組成物および方法

Country Status (8)

Country Link
US (1) US20060051374A1 (enExample)
EP (1) EP1755665A4 (enExample)
JP (1) JP2008505857A (enExample)
CN (1) CN101426524A (enExample)
BR (1) BRPI0510430A (enExample)
CA (1) CA2564855A1 (enExample)
MX (1) MXPA06012451A (enExample)
WO (1) WO2006126981A2 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040265351A1 (en) 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
ES2406730T3 (es) * 2003-08-27 2013-06-07 3M Innovative Properties Company Imidazoquinolinas sustituidas con ariloxi y arilalquilenoxi
NZ546274A (en) 2003-10-03 2009-12-24 3M Innovative Properties Co Pyrazolopyridines and analags thereof
AR046046A1 (es) 2003-10-03 2005-11-23 3M Innovative Properties Co Imidazoquinolinas alcoxi sustituidas. composiciones farmaceuticas.
MXPA06005910A (es) 2003-11-25 2006-08-23 3M Innovative Properties Co Sistemas de anillo imidazo sustituido y metodos.
US8541438B2 (en) * 2004-06-18 2013-09-24 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
ES2392648T3 (es) 2004-12-30 2012-12-12 3M Innovative Properties Company Compuestos quirales sustituidos que contienen un núcleo 1,2-imidazo-4,5-c condensado
JP5543068B2 (ja) * 2004-12-30 2014-07-09 スリーエム イノベイティブ プロパティズ カンパニー キラル縮合［１，２］イミダゾ［４，５−ｃ］環状化合物
NZ560543A (en) * 2005-01-28 2012-01-12 Galenbio Inc Immunologically active compositions using pathogen associated molecular patterns (PAMP)
WO2007120121A2 (en) 2005-02-09 2007-10-25 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted thiazolo[4,5-c] ring compounds and methods
EP1846419B1 (en) 2005-02-09 2014-04-16 3M Innovative Properties Company Alkoxy-substituted thiazoloquinolines and thiazolonaphthyridines
US8658666B2 (en) * 2005-02-11 2014-02-25 3M Innovative Properties Company Substituted imidazoquinolines and imidazonaphthyridines
AU2006216686A1 (en) * 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Method of preferentially inducing the biosynthesis of interferon
JP2008531568A (ja) 2005-02-23 2008-08-14 コーリー ファーマシューティカル グループ，インコーポレイテッド ヒドロキシアルキルで置換されたイミダゾナフチリジン
US8158794B2 (en) * 2005-02-23 2012-04-17 3M Innovative Properties Company Hydroxyalkyl substituted imidazoquinoline compounds and methods
JP2008543725A (ja) * 2005-02-23 2008-12-04 コーリー ファーマシューティカル グループ，インコーポレイテッド ヒドロキシアルキル置換イミダゾキノリン
AU2006241166A1 (en) * 2005-04-25 2006-11-02 3M Innovative Properties Company Immunostimulatory compositions
CA2621831A1 (en) * 2005-09-09 2007-03-15 Coley Pharmaceutical Group, Inc. Amide and carbamate derivatives of n-{2-[4-amino-2- (ethoxymethyl)-1h-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl}methanesulfonamide and methods
ZA200803029B (en) 2005-09-09 2009-02-25 Coley Pharm Group Inc Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
JP5247458B2 (ja) * 2005-11-04 2013-07-24 スリーエム・イノベイティブ・プロパティーズ・カンパニー ヒドロキシ及びアルコキシ置換１ｈ−イミダゾキノリン及び方法
EP1988896A4 (en) 2006-02-22 2011-07-27 3M Innovative Properties Co CONJUGATES TO MODIFY IMMUNE REACTIONS
US8329721B2 (en) * 2006-03-15 2012-12-11 3M Innovative Properties Company Hydroxy and alkoxy substituted 1H-imidazonaphthyridines and methods
WO2008030511A2 (en) * 2006-09-06 2008-03-13 Coley Pharmaceuticial Group, Inc. Substituted 3,4,6,7-tetrahydro-5h, 1,2a,4a,8-tetraazacyclopenta[cd]phenalenes
MX344330B (es) * 2008-03-24 2016-12-13 4Sc Ag Imidazoquinolinas substituidas novedosas.
BRPI0919937A2 (pt) * 2008-10-24 2016-02-16 Glaxosmithkline Biolog Sa composto, e, método para melhorar a atividade de adjuvante de uma imidazoquinolina
CA2808624C (en) 2010-08-17 2019-05-14 3M Innovative Properties Company Lipidated immune response modifier compound compositions, formulations, and methods
CA2838158C (en) 2011-06-03 2019-07-16 3M Innovative Properties Company Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom
EP3366311B1 (en) 2011-06-03 2020-02-26 3M Innovative Properties Co. Hydrazino-1h-imidazoquinolin-4-amines and conjugates made therefrom
CA3086439A1 (en) 2017-12-20 2019-06-27 3M Innovative Properties Company Amide substitued imidazo[4,5-c]quinoline compounds with a branched chain linking group for use as an immune response modifier
EP3941520A4 (en) * 2019-03-20 2022-08-31 Advagene Biopharma Co., Ltd. METHOD OF MODULATING MUCOSAL IMMUNOGENICITY

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL73534A (en) * 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
ZA848968B (en) * 1983-11-18 1986-06-25 Riker Laboratories Inc 1h-imidazo(4,5-c)quinolines and 1h-imidazo(4,5-c)quinolin-4-amines
US5238944A (en) * 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US5756747A (en) * 1989-02-27 1998-05-26 Riker Laboratories, Inc. 1H-imidazo 4,5-c!quinolin-4-amines
US4929624A (en) * 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
US5037986A (en) * 1989-03-23 1991-08-06 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo[4,5-c]quinolin-4-amines
US5824313A (en) * 1989-09-25 1998-10-20 University Of Utah Research Foundation Vaccine compositions and method for induction of mucosal immune response via systemic vaccination
US4988815A (en) * 1989-10-26 1991-01-29 Riker Laboratories, Inc. 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines
HU217080B (hu) * 1990-10-05 1999-11-29 Minnesota Mining And Manufacturing Co. Új eljárás imidazo[4,5-c]kinolin-4-amin-származékok előállítására
US5175296A (en) * 1991-03-01 1992-12-29 Minnesota Mining And Manufacturing Company Imidazo[4,5-c]quinolin-4-amines and processes for their preparation
US5389640A (en) * 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5268376A (en) * 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5266575A (en) * 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
IL105325A (en) * 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
US5395937A (en) * 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
CZ288182B6 (en) * 1993-07-15 2001-05-16 Minnesota Mining & Mfg Imidazo[4,5-c]pyridine-4-amines and pharmaceutical preparations based thereon
US5352784A (en) * 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
DE4341564A1 (de) * 1993-12-07 1995-06-08 Bosch Gmbh Robert Aggregat zum Fördern von Kraftstoff aus einem Vorratstank zur Brennkraftmaschine eines Kraftfahrzeuges
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
DE69535905D1 (de) * 1994-07-15 2009-02-26 Coley Pharm Group Inc Immunomodulatorische Oligonukleotide
US6239116B1 (en) * 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5482936A (en) * 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
US5741908A (en) * 1996-06-21 1998-04-21 Minnesota Mining And Manufacturing Company Process for reparing imidazoquinolinamines
KR19990044383A (ko) * 1996-07-03 1999-06-25 나가시마 카쭈시게, 노미야마 아키히코 신규 퓨린 유도체
US6387938B1 (en) * 1996-07-05 2002-05-14 Mochida Pharmaceutical Co., Ltd. Benzimidazole derivatives
ES2290969T3 (es) * 1996-10-25 2008-02-16 Minnesota Mining And Manufacturing Company Compuestos modificadores de la respuesta inmune para el tratamiento de enfermedades mediadas por th2 y relacionadas.
US5939090A (en) * 1996-12-03 1999-08-17 3M Innovative Properties Company Gel formulations for topical drug delivery
WO1998030562A1 (en) * 1997-01-09 1998-07-16 Terumo Kabushiki Kaisha Novel amide derivatives and intermediates for the synthesis thereof
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6426334B1 (en) * 1997-04-30 2002-07-30 Hybridon, Inc. Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal
US6113918A (en) * 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en) * 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
WO1998052581A1 (en) * 1997-05-20 1998-11-26 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
UA67760C2 (uk) * 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
TW572758B (en) * 1997-12-22 2004-01-21 Sumitomo Pharma Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives
US6110929A (en) * 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
JP2000119271A (ja) * 1998-08-12 2000-04-25 Hokuriku Seiyaku Co Ltd １ｈ―イミダゾピリジン誘導体
US6245776B1 (en) * 1999-01-08 2001-06-12 3M Innovative Properties Company Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
US20020058674A1 (en) * 1999-01-08 2002-05-16 Hedenstrom John C. Systems and methods for treating a mucosal surface
US6558951B1 (en) * 1999-02-11 2003-05-06 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
US6541485B1 (en) * 1999-06-10 2003-04-01 3M Innovative Properties Company Urea substituted imidazoquinolines
US6331539B1 (en) * 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US6451810B1 (en) * 1999-06-10 2002-09-17 3M Innovative Properties Company Amide substituted imidazoquinolines
US6573273B1 (en) * 1999-06-10 2003-06-03 3M Innovative Properties Company Urea substituted imidazoquinolines
US6756382B2 (en) * 1999-06-10 2004-06-29 3M Innovative Properties Company Amide substituted imidazoquinolines
JP5268214B2 (ja) * 1999-08-13 2013-08-21 イデラ ファーマシューティカルズ インコーポレイテッド ヌクレオシドの位置的修飾によるオリゴヌクレオチドＣｐＧ−媒体免疫刺激の変調
US6376669B1 (en) * 1999-11-05 2002-04-23 3M Innovative Properties Company Dye labeled imidazoquinoline compounds
US20040023870A1 (en) * 2000-01-21 2004-02-05 Douglas Dedera Methods of therapy and diagnosis using targeting of cells that express toll-like receptor proteins
GB0001704D0 (en) * 2000-01-25 2000-03-15 Glaxo Group Ltd Protein
WO2001070663A2 (en) * 2000-03-17 2001-09-27 Corixa Corporation Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors
US6894060B2 (en) * 2000-03-30 2005-05-17 3M Innovative Properties Company Method for the treatment of dermal lesions caused by envenomation
US20020055517A1 (en) * 2000-09-15 2002-05-09 3M Innovative Properties Company Methods for delaying recurrence of herpes virus symptoms
US6677348B2 (en) * 2000-12-08 2004-01-13 3M Innovative Properties Company Aryl ether substituted imidazoquinolines
AU2002232498B2 (en) * 2000-12-08 2006-05-04 3M Innovative Properties Company Screening method for identifying compounds that selectively induce interferon alpha
US6525064B1 (en) * 2000-12-08 2003-02-25 3M Innovative Properties Company Sulfonamido substituted imidazopyridines
US6545016B1 (en) * 2000-12-08 2003-04-08 3M Innovative Properties Company Amide substituted imidazopyridines
US6677347B2 (en) * 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
AU2006216669A1 (en) * 2000-12-08 2006-08-31 3M Innovative Properties Company Compositions and methods for targeted delivery of immune response modifiers
CA2458876A1 (en) * 2001-08-30 2003-03-13 3M Innovative Properties Company Methods of maturing plasmacytoid dendritic cells using immune response modifier molecules
US20030139364A1 (en) * 2001-10-12 2003-07-24 University Of Iowa Research Foundation Methods and products for enhancing immune responses using imidazoquinoline compounds
US20040014779A1 (en) * 2001-11-16 2004-01-22 3M Innovative Properties Company Methods and compositions related to IRM compounds and toll-like recptor pathways
KR100718371B1 (ko) * 2001-11-27 2007-05-14 애나디스 파마슈티칼스, 인코포레이티드 ３-β-Ｄ-리보푸라노실티아졸로[４,５-ｄ]피리디민누클레오시드 및 이의 용도
DE60228611D1 (de) * 2001-11-29 2008-10-09 3M Innovative Properties Co Pharmazeutische formulierung umfassend ein die immunantwort modifizierendes mittel
US6677349B1 (en) * 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US6525028B1 (en) * 2002-02-04 2003-02-25 Corixa Corporation Immunoeffector compounds
CA2475595C (en) * 2002-02-22 2012-07-10 3M Innovative Properties Company Method of reducing and preventing uvb-induced immunosuppression
US20030185835A1 (en) * 2002-03-19 2003-10-02 Braun Ralph P. Adjuvant for vaccines
US6743920B2 (en) * 2002-05-29 2004-06-01 3M Innovative Properties Company Process for imidazo[4,5-c]pyridin-4-amines
WO2003103584A2 (en) * 2002-06-07 2003-12-18 3M Innovative Properties Company Ether substituted imidazopyridines
ATE488246T1 (de) * 2002-08-15 2010-12-15 3M Innovative Properties Co Immunstimulatorische zusammensetzungen und verfahren zur stimulierung einer immunantwort
JP2006503068A (ja) * 2002-09-26 2006-01-26 スリーエム イノベイティブ プロパティズ カンパニー １ｈ−イミダゾダイマー
WO2004053452A2 (en) * 2002-12-11 2004-06-24 3M Innovative Properties Company Assays relating to toll-like receptor activity
CA2510375A1 (en) * 2002-12-20 2004-07-15 3M Innovative Properties Company Aryl / hetaryl substituted imidazoquinolines
JP2006512391A (ja) * 2002-12-30 2006-04-13 スリーエム イノベイティブ プロパティズ カンパニー 組み合わせ免疫賦活薬
JP2006517974A (ja) * 2003-02-13 2006-08-03 スリーエム イノベイティブ プロパティズ カンパニー Ｉｒｍ化合物およびトル様受容体８に関する方法および組成物
JP2006519020A (ja) * 2003-02-27 2006-08-24 スリーエム イノベイティブ プロパティズ カンパニー Ｔｌｒ介在生物活性の選択的調節
WO2004078138A2 (en) * 2003-03-04 2004-09-16 3M Innovative Properties Company Prophylactic treatment of uv-induced epidermal neoplasia
JP2006519877A (ja) * 2003-03-07 2006-08-31 スリーエム イノベイティブ プロパティズ カンパニー １−アミノ１ｈ−イミダゾキノリン
WO2004080293A2 (en) * 2003-03-13 2004-09-23 3M Innovative Properties Company Methods for diagnosing skin lesions
EP1603476A4 (en) * 2003-03-13 2010-01-13 3M Innovative Properties Co PROCESS FOR REMOVING TATTOO
NZ567227A (en) * 2003-03-13 2010-01-29 3M Innovative Properties Co Methods of improving skin quality through topical application of an immune response modifier such as imiquimod
US20040191833A1 (en) * 2003-03-25 2004-09-30 3M Innovative Properties Company Selective activation of cellular activities mediated through a common toll-like receptor
US20040192585A1 (en) * 2003-03-25 2004-09-30 3M Innovative Properties Company Treatment for basal cell carcinoma
WO2004108072A2 (en) * 2003-04-10 2004-12-16 3M Innovative Properties Company Delivery of immune response modifier compounds using metal-containing particulate support materials
EP1617845A4 (en) * 2003-04-28 2006-09-20 3M Innovative Properties Co COMPOSITIONS AND METHODS FOR INDUCING OPOID RECEPTORS
US7731967B2 (en) * 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
EP1660122A4 (en) * 2003-08-25 2007-10-24 3M Innovative Properties Co IMMUNOSTIMULATORY COMBINATIONS AND TREATMENTS
ES2342069T4 (es) * 2003-09-05 2011-01-26 Anadys Pharmaceuticals, Inc. Ligandos de tlr7 para el tratamiento de la hepatitis c.
US20050096259A1 (en) * 2003-10-31 2005-05-05 3M Innovative Properties Company Neutrophil activation by immune response modifier compounds
US20060045885A1 (en) * 2004-08-27 2006-03-02 Kedl Ross M Method of eliciting an immune response against HIV
WO2006029223A2 (en) * 2004-09-08 2006-03-16 Children's Medical Center Corporation Method for stimulating the immune response of newborns

Similar Documents

Publication Publication Date Title
JP2008505857A5 (enExample)
WO2006126981A3 (en) Compositions and methods for mucosal vaccination
JP2007527914A5 (enExample)
JP2009536147A5 (enExample)
JP2007509067A5 (enExample)
JP2012500090A5 (enExample)
AR060931A1 (es) Producto farmaceutico recubierto para la administracion intraoral de nicotina y su uso y elaboracion
JP2009502743A5 (enExample)
CA2683786C (en) Use of tapentadol in the treatment of pain and with a reduced incidence of tapentadol-induced side-effects
JP2011511805A5 (enExample)
JP2007501251A5 (enExample)
ATE507840T1 (de) Hilfszusammensetzung für vakzinen, die über die schleimhaut oder durch injektion verabreicht werden
FI3782612T3 (fi) Sytidiinianalogien oraalisia formulaatioita ja menetelmiä niiden käyttämiseksi
JP2012502037A5 (enExample)
JP2012193216A5 (enExample)
JP2005503399A5 (enExample)
WO2007012022A3 (en) Unit dose form with ibuprofen-famotidine admixture
AR062659A1 (es) Composicion de liberacion sostenida de levodopa y metodo para su uso
JP2007536277A5 (enExample)
JP2013541583A5 (enExample)
ECSP11011289A (es) Formulaciones galénicas de compuestos orgánicos
WO2008011426A3 (en) Methods and medicaments for administration of ibuprofen
JP2015510928A5 (enExample)
NZ578065A (en) Methods for treating psoriasis with an antibody which binds to an epitope
JP2020533302A5 (enExample)